Cargando…

Time of Initiating Enzyme Replacement Therapy Affects Immune Abnormalities and Disease Severity in Patients with Gaucher Disease

Gaucher disease (GD) patients often present with abnormalities in immune response that may be the result of alterations in cellular and/or humoral immunity. However, how the treatment and clinical features of patients impact the perturbation of their immunological status remains unclear. To address...

Descripción completa

Detalles Bibliográficos
Autores principales:	Limgala, Renuka Pudi, Ioanou, Chidima, Plassmeyer, Matthew, Ryherd, Mark, Kozhaya, Lina, Austin, Lauren, Abidoglu, Cem, Unutmaz, Derya, Alpan, Oral, Goker-Alpan, Ozlem
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5152900/ https://www.ncbi.nlm.nih.gov/pubmed/27942037 http://dx.doi.org/10.1371/journal.pone.0168135

Ejemplares similares

Effect of Substrate Reduction Therapy in Comparison to Enzyme Replacement Therapy on Immune Aspects and Bone Involvement in Gaucher Disease
por: Limgala, Renuka P., et al.
Publicado: (2020)

Biofabrication of an in-vitro bone model for Gaucher disease
por: Banerjee, Dishary, et al.
Publicado: (2023)

Impaired autophagic and mitochondrial functions are partially restored by ERT in Gaucher and Fabry diseases
por: Ivanova, Margarita M., et al.
Publicado: (2019)

Optimal therapy in Gaucher disease
por: Goker-Alpan, Ozlem
Publicado: (2010)

Gaucher Disease and the Synucleinopathies
por: Hruska, Kathleen S., et al.
Publicado: (2006)

The Interaction of Innate and Adaptive Immunity and Stabilization of Mast Cell Activation in Management of Infusion Related Reactions in Patients with Fabry Disease
por: Limgala, Renuka P., et al.
Publicado: (2020)

TRAP5b and RANKL/OPG Predict Bone Pathology in Patients with Gaucher Disease
por: Ivanova, Margarita, et al.
Publicado: (2021)

Pregnancy Outcomes in Late Onset Pompe Disease
por: Goker-Alpan, Ozlem, et al.
Publicado: (2020)

Selective screening for lysosomal storage disorders in a large cohort of minorities of African descent shows high prevalence rates and novel variants
por: Limgala, Renuka Pudi, et al.
Publicado: (2021)

Characteristics of 26 patients with type 3 Gaucher disease: A descriptive analysis from the Gaucher Outcome Survey
por: Schwartz, Ida Vanessa D., et al.
Publicado: (2017)

Switching between Enzyme Replacement Therapies and Substrate Reduction Therapies in Patients with Gaucher Disease: Data from the Gaucher Outcome Survey (GOS)
por: Hughes, Derralynn A., et al.
Publicado: (2022)

Wnt signaling pathway inhibitors, sclerostin and DKK-1, correlate with pain and bone pathology in patients with Gaucher disease
por: Ivanova, Margarita M., et al.
Publicado: (2022)

Gaucher Disease in Bone: From Pathophysiology to Practice
por: Hughes, Derralynn, et al.
Publicado: (2019)

Clinical course and prognosis in patients with Gaucher disease and parkinsonism
por: Lopez, Grisel, et al.
Publicado: (2016)

A Pilot Study of Omalizumab in Eosinophilic Esophagitis
por: Loizou, Denise, et al.
Publicado: (2015)

Towards standardizing basophil identification by flow cytometry
por: Sonder, Soren Ulrik, et al.
Publicado: (2023)

Demographics and patient characteristics of 1209 patients with Gaucher disease: Descriptive analysis from the Gaucher Outcome Survey (GOS)
por: Zimran, Ari, et al.
Publicado: (2017)

A multicenter open-label treatment protocol (HGT-GCB-058) of velaglucerase alfa enzyme replacement therapy in patients with Gaucher disease type 1: safety and tolerability
por: Pastores, Gregory M., et al.
Publicado: (2014)

Cellular and biochemical response to chaperone versus substrate reduction therapies in neuropathic Gaucher disease
por: Ivanova, Margarita M., et al.
Publicado: (2021)

Reply to Mistry et al. The Two Substrate Reduction Therapies for Type 1 Gaucher Disease Are Not Equivalent. Comment on “Hughes et al. Switching between Enzyme Replacement Therapies and Substrate Reduction Therapies in Patients with Gaucher Disease: Data from the Gaucher Outcome Survey (GOS). J. Clin. Med. 2022, 11, 5158”
por: Hughes, Derralynn A., et al.
Publicado: (2023)

SARS-CoV-2 specific antibody and neutralization assays reveal the wide range of the humoral immune response to virus
por: Dogan, Mikail, et al.
Publicado: (2021)

The definition of neuronopathic Gaucher disease
por: Schiffmann, Raphael, et al.
Publicado: (2020)

Expression and Function of TNF and IL-1 Receptors on Human Regulatory T Cells
por: Mercer, Frances, et al.
Publicado: (2010)

Inflammasome activation and pyroptosis in lymphopenic liver patients with COVID-19
por: Kroemer, Alexander, et al.
Publicado: (2020)

Stability is maintained in adults with Gaucher disease type 1 switched from velaglucerase alfa to eliglustat or imiglucerase: A sub-analysis of the eliglustat ENCORE trial
por: Pleat, Rebecca, et al.
Publicado: (2016)

Gaucher disease and SARS-CoV-2 infection: Emerging management challenges
por: Mistry, Pramod, et al.
Publicado: (2020)

Presenting signs and patient co‐variables in Gaucher disease: outcome of the Gaucher Earlier Diagnosis Consensus (GED‐C) Delphi initiative
por: Mehta, Atul, et al.
Publicado: (2019)

Circulated TGF-β1 and VEGF-A as Biomarkers for Fabry Disease-Associated Cardiomyopathy
por: Ivanova, Margarita M., et al.
Publicado: (2023)

An open-label clinical trial of agalsidase alfa enzyme replacement therapy in children with Fabry disease who are naïve to enzyme replacement therapy
por: Goker-Alpan, Ozlem, et al.
Publicado: (2016)

Identification of a Regulatory T Cell Specific Cell Surface Molecule that Mediates Suppressive Signals and Induces Foxp3 Expression
por: Wang, Rui, et al.
Publicado: (2008)

Development and validation of Gaucher disease type 1 (GD1)-specific patient-reported outcome measures (PROMs) for clinical monitoring and for clinical trials
por: Elstein, Deborah, et al.
Publicado: (2022)

The Metalloprotease ADAM12 Regulates the Effector Function of Human Th17 Cells
por: Zhou, Angela X., et al.
Publicado: (2013)

Elimination of HIV-1-Infected Primary T Cell Reservoirs in an In Vitro Model of Latency
por: Rawlings, Stephen A., et al.
Publicado: (2015)

Targeting SARS‐CoV‐2 infection through CAR‐T‐like bispecific T cell engagers incorporating ACE2
por: Dogan, Mikail, et al.
Publicado: (2022)

Immunoglobulin Abnormalities in Gaucher Disease: an Analysis of 278 Patients Included in the French Gaucher Disease Registry
por: Nguyen, Yann, et al.
Publicado: (2020)

Induction of Eosinophilic Esophagitis by Sublingual Pollen Immunotherapy
por: Miehlke, Stephan, et al.
Publicado: (2013)

Probing the Effector and Suppressive Functions of Human T Cell Subsets Using Antigen-Specific Engineered T Cell Receptors
por: Wan, Qi, et al.
Publicado: (2013)

Correction: Probing the Effector and Suppressive Functions of Human T Cell Subsets Using Antigen-Specific Engineered T Cell Receptors
por: Wan, Qi, et al.
Publicado: (2013)

Enzyme Replacement in Gaucher Disease
por: Beutler, Ernest
Publicado: (2004)

Rapid Clathrin-Mediated Uptake of Recombinant α-Gal-A to Lysosome Activates Autophagy
por: Ivanova, Margarita M., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_kp2v8o9bg9b1bh6ni11754a4m4